Health Care·Biotechnology·$11.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.57 | N/A | -7442.86% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-2.57 | N/A | -7442.86% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management's tone was defensive, reflecting the company's current challenges. There was no forward guidance provided, leaving investors uncertain.
Management did not provide specific guidance for future quarters.
The company acknowledged challenges but did not elaborate on strategies.
Madrigal Pharmaceuticals reported a significant loss per share, which disappointed investors and led to an 11.11% drop in stock price. The lack of revenue data and guidance adds to the uncertainty surrounding the company's future performance. Investors may be concerned about the company's ability to navigate its current challenges without clear direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PALO ALTO NETWORKS I
Feb 17, 2026